Adoption of Advanced Brain Tumor Imaging Platform
Imaging Biometrics Limited
("Imaging Biometrics", the "Company" or, together with its subsidiaries, the "Group")
Imaging Biometrics Expands Market Presence with Adoption of Advanced Brain Tumor Imaging Platform by Leading Regional Healthcare System
Imaging Biometrics Limited (LSE: IBAI) announces that its wholly owned US subsidiary, Imaging Biometrics LLC ("IB"), has entered into an annual subscription agreement with a leading health system for IB's quantitative neuro-oncology imaging software including IB Neuro, IB Delta T1, and IB FTBx.
The healthcare organization is among the first in the region to provide access to IB's advanced quantitative MRI technologies, bringing objective, standardized imaging biomarkers to neuro-oncology care and supporting more informed clinical decision-making throughout the patient journey.
Unlike conventional imaging approaches that rely on subjective interpretation or labor-intensive workflows, Imaging Biometrics' software automatically generates standardized, quantitative imaging biomarkers from routine MRI exams. By transforming complex imaging data into objective measures of tumor biology, the platform helps clinicians make more confident, consistent, and informed treatment decisions.
"This implementation reflects the continued evolution of neuro-oncology toward objective, quantitative imaging biomarkers that can support more confident clinical decision-making. By standardizing the assessment of tumor physiology and treatment response, our platform helps address some of the most significant challenges in brain tumor management. We are encouraged by the growing adoption of these technologies as healthcare systems seek proven solutions that can improve both clinical workflows and patient care," said Michael Schmainda, CEO of IB.
Trevor Brown, Chief Executive Officer of Imaging Biometrics Limited, said: "This is the second major new installation this quarter, testament to our increasingly relevant software."
--ENDS-
For further information, please contact:
|
Imaging Biometrics Limited Trevor Brown/Brett Skelly/Michael Schmainda/John Richardson Tel: 020 7469 0930 |
|
AlbR Capital Limited (Broker) Lucy Williams Tel: 020 7220 9797 |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE